摘要
5-氟尿嘧啶(5-Fu)仍是目前结直肠癌一线化疗方案的基础药物。大量研究聚焦于预测5-Fu疗效或不良反应的基因多态性位点。TYMS、DPYD、MTHFR等基因的多个多态性位点可能在其中发挥了作用。然而,目前很少能就同一多态性位点对治疗效果的影响得出统一结论。采用全基因组测序及多基因联合分析有可能在该领域开展更全面深入的研究。文章对基于5-Fu的结直肠癌化疗疗效或不良反应的相关基因多态性研究进展进行综述。
5-fluorouracil (5-Fu) has been the basic drug in the first-line chemotherapy for colorectal cancer so far. A large number of studies have focused on the discovery of gene polymorphism sites for predicting the efficacy or adverse reactions of 5-Fu. Multiple polymorphic sites of genes such as TYMS, DPYD, and MTHFR may play a role in it. However, no consistent conclusion has been reached over the effect of same polymorphic site on the therapeutic outcome. The application of whole genome sequencing and multi-gene joint analysis may carry out more comprehensive and in-depth researches in the future. This paper reviews the progress of related gene polymorphism of 5-Fu-based chemotherapy efficacy and adverse reactions in colorectal cancer.
作者
李婷婷
谢颖
何林海
王震
Li Tingting;Xie Ying;He Linhai;Wang Zhen(Department of Clinical Pharmacy, the People's Hospital of Jinghong City of Xishuangbanna Dai Nationality Autonomous Prefecture of Yunnan Province, Jinghong 666100, China;Department of General Surgery, the People's Hospital of Jinghong City of Xishuangbanna Dai Nationality Autonomous Prefecture of Yunnan Province, Jinghong 666100, China)
出处
《肿瘤研究与临床》
CAS
2019年第9期644-648,共5页
Cancer Research and Clinic
基金
云南省高层次卫生计生技术人才培养专项资助.
